Olink® Signature Q100 now available: A user friendly desktop instrument to broaden access to Olink's multiplex protein analysis platformGlobeNewsWire • 11/23/21
Olink Holding AB (publ) (OLK) CEO Jon Heimer on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/13/21
Psomagen, Inc. Is Partnering with Olink Proteomics, Enabling Unprecedented Multi-Omics Clinical StudiesBusiness Wire • 11/11/21
Fulgent Genetics Offers Multi-Omic Solutions to Pharma through Addition of Olink Proteomics PlatformGlobeNewsWire • 11/04/21
CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global servicesGlobeNewsWire • 08/31/21
Olink Holding AB (publ) (OLK) Management on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/11/21
Olink: CORAL to use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseasesGlobeNewsWire • 07/27/21
UK Biobank-PPP expands proteomics study of 53,000 participants to Olink Explore 3072GlobeNewsWire • 07/21/21
Olink Holding AB (publ) Launches Public Offering of American Depositary Shares by Selling ShareholdersGlobeNewsWire • 07/12/21
Olink: SCALLOP launches clinical trial arm to uncover next level of drug target insights from proteomic profilingGlobeNewsWire • 06/15/21
Announcing Olink Signature Q100: facilitating access for researchers to Olink technology with a benchtop system dedicated to multiplex protein biomarker measurementGlobeNewsWire • 06/02/21
Olink to present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceGlobeNewsWire • 05/25/21
Olink reports first quarter 2021 financial results and issues full year 2021 guidanceGlobeNewsWire • 05/20/21